VivoSeq
Ophthalmology

Blepharitis

26

Pipeline Programs↗

2

Active Trials↗

9

Companies Involved↗

Blepharitis is an emerging landscape with 26 programs across 9 companies. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Aperta Biosciences, LLC, GSK. 9 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

11/100

Mech. Concentration

20/100

Completion Rate

91/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

2 programs

Phase 2A

Aperta Biosciences, LLC

1 program

Phase 2GSK logo

GSK

1 program

Phase 2Sun Pharmaceutical Industries Limited logo

Sun Pharmaceutical Industries Limited

1 program

Phase 3Merck & Co. logo

Merck & Co.

2 programs

Phase 3V

Viatris Specialty LLC

1 program

Approved

Pipeline

Programs by Phase

Preclinical3

Povidone-Iodine

Becton, Dickinson and Company

Tobramycin-Dexmethasone

Southern California Institute for Research and Education

Tetracycline: Doxycycline Analog

University of Texas Southwestern Medical Center

Phase 12

Anakinra

Swedish Orphan Biovitrum

Terpinen-4-Ol

BioTissue Holdings, Inc

Phase 27

Fluticasone Propionate

GSK

Azithromycin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Doxycycline

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

GLK-321 Low Dose BID

Glaukos Corporation

NCX 470

Nicox Ophthalmics, Inc.

Phase 35

Dexamethasone

Aspen Global Incorporated

TOBRADEX

Alcon Research

Azasite

Merck & Co.

TP-03

Tarsus Pharmaceuticals, Inc.

ISV-305

Sun Pharmaceutical Industries Limited

Approved9

Tobramycin

Viatris Specialty LLC

Pimecrolimus

Bausch Health Americas, Inc.

Ivermectin

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Erythromycin

Azurity Pharmaceuticals

Levofloxacin

Wim Janssens

Analysis

Trial Status

37

clinical trials

Completed29 · 78%
Unknown status3 · 8%
Recruiting2 · 5%
Terminated2 · 5%
Withdrawn1 · 3%

Clinical Trials

Trial Activity

37 trials

Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis
Recruiting·GGlaukos Corporation·Phase 2·NCT07400965·250 enrolled
A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis.
Recruiting·AAperta Biosciences, LLC·Phase 2·NCT06720896·100 enrolled
Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction
Completed·AAxeroVision, Inc.·Phase 2·NCT04469998·129 enrolled
Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis
Completed·Merck & Co. logoMerck & Co.·Phase 4·NCT00656539·20 enrolled
Demodex Blepharitis Treatment Study
Completed·BBioTissue Holdings, Inc·Phase 1·NCT01647217·17 enrolled
Treatment of Patients With Blepharitis and Facial Rosacea
Completed·GGalderma R&D·Phase 2·NCT00560703·70 enrolled
Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis
Completed·Merck & Co. logoMerck & Co.·Phase 4·NCT00629941·25 enrolled
Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis
Completed·Merck & Co. logoMerck & Co.·Phase 4·NCT00629590·20 enrolled
Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis
Completed·MMassachusetts Eye and Ear Infirmary·Phase 4·NCT01456780·60 enrolled
Efficacy and Safety of Posiformin 2 % Eye Ointment in the Treatment of Blepharitis
Completed·UUrsapharm Arzneimittel GmbH·Phase 4·NCT01357538·197 enrolled
Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis
Completed·—·Phase 4·NCT01478256·30 enrolled
Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers
Completed·TTarsus Pharmaceuticals, Inc.·Phase 4·NCT06182358·145 enrolled
TTO Swabs Versus Baby Shampoo in Patients With Seborrehic Blepharitis
Completed·IIstanbul University - Cerrahpasa·Phase 4·NCT04678531·49 enrolled
Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis
Completed·Merck & Co. logoMerck & Co.·Phase 4·NCT00629980·60 enrolled
Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis
Completed·NNicox Ophthalmics, Inc.·Phase 2·NCT03926026·36 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)